Pharmacological treatment of monogenic disease

Pharmacogenomics Journal

Volumn 3, Issue 5, 2003, Pages 264-266

  Weatherall, D J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; ARGININE BUTYRATE; AZACITIDINE; BETA GLOBIN; BISPHOSPHONIC ACID DERIVATIVE; BUTYRIC ACID; BUTYRIC ACID DERIVATIVE; DNA; DYSTROPHIN; HEMOGLOBIN A; HEMOGLOBIN F; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; MESSENGER RNA; POLOXAMER; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDOXINE; RESIN; SODIUM PHENYLBUTYRATE; THIAMINE; UNCLASSIFIED DRUG; UTROPHIN;

ARTICLE; BETA THALASSEMIA; BONE MARROW DEPRESSION; CLINICAL TRIAL; DNA METHYLATION; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; GENE ACTIVATION; GENE THERAPY; GENETIC HETEROGENEITY; HOMOCYSTINURIA; HUMAN; HYPERCHOLESTEROLEMIA; LEUKEMIA; MAPLE SYRUP URINE DISEASE; MOLECULAR GENETICS; MONOGENIC DISORDER; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL; SICKLE CELL ANEMIA; TYROSINEMIA;

ANEMIA, SICKLE CELL; ANIMALS; GENETIC DISEASES, INBORN; GENETIC MARKERS; HEMOGLOBINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PHENYLKETONURIAS;

ACER;

EID: 0242407562     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500198     Document Type: Article

References (15)

1. Treacy EP et al . Treatment of genetic disease. In: The Metabolic Basis of Inherited Disease, ed. Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D. 8th Edn. McGraw Hill: New York 2003: 175-192.
2. Weatherall DJ, Clegg JB The Thalassaemia Syndromes, 4th Edn. Blackwell Scientific Publishers: Oxford 2001.
3. Atweh GF, Schechter AN. Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. Curr Opin Hemotol 2001; 8: 123-130.
4. Ley TJ et al. 5-Azacytidine increases γ-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 1983; 62: 370-380.
5. Platt OS et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984; 74: 652-656.
6. Charache S et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Eng J Med 1995; 332: 1317-1322.
7. Steinberg MH et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia. Risks and benefits up to 9 years of treatement. J Am Med Assoc 2003; 289: 1645-1651.
8. Mentzer W. Bone marrow transplantation for haemoglobinopathies. Curr Opin Hematol 2000; 7: 95-100.
9. Bradai M et al. Hydroxyurea can eliminate transfusion requirements in children with severe beta thalassemia. Blood 2003; 102: 1529-1530.
10. Olivieri NF et al. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet 1997; 350: 491-492.
11. Atweh GF et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 1999; 93: 1790-1797.
12. DeSimone J et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 2002; 99: 3905-3908.
13. Orringer EP et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease. A randomized controlled trial. J Am Med Assoc 2001; 286: 2099-2106.
14. Deconinck N et al. Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice. Nat Med 1997; 3: 1216-1221.
15. Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet 2001; 2: 245-255.